drugset / Trial / NCT01413906
Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the tolerability and safety profile of BMS-833923 (XL139) when orally administered on a once daily schedule.
Timeline
- Start
- 2011-11
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-833923 | Small molecule | 150 mg | Oral |
| Subject | BMS-833923 | Small molecule | 300 mg | Oral |
| Subject | BMS-833923 | Small molecule | 450 mg | Oral |